205756-46-3

Basic information

• Product Name: N-(3,4-DIFLUOROPHENYL)-2,2-DIMETHYLPROPIONAMIDE
• Synonyms: N-(3,4-DIFLUOROPHENYL)-2,2-DIMETHYLPROPIONAMIDE
• CAS NO: 205756-46-3
• Molecular Formula: C₁₁H₁₃F₂NO
• Molecular Weight: 213.2238264
• Mol File: 205756-46-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(3,4-DIFLUOROPHENYL)-2,2-DIMETHYLPROPIONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,4-DIFLUOROPHENYL)-2,2-DIMETHYLPROPIONAMIDE(205756-46-3)
• EPA Substance Registry System: N-(3,4-DIFLUOROPHENYL)-2,2-DIMETHYLPROPIONAMIDE(205756-46-3)

Safety Data

• Hazardous Substances Data: 205756-46-3(Hazardous Substances Data)

Upstream product

• 3282-30-2 pivaloyl chloride 
• 3863-11-4 3,4-difluoroaniline 

Downstream Products

• 220705-66-8 N-[3,4-Difluoro-2-(2,2,2-trifluoro-acetyl)-phenyl]-2,2-dimethyl-propionamide 
• 114153-09-2 3,4-Difluoro-2-methylaniline 
• 1100761-59-8 N-[3,4-difluoro-2-(4-fluorobenzoyl)phenyl]-2,2-dimethylpropanamide 
• 698395-61-8 C₁₇H₁₈F₂N₂O₂ 
• 205756-47-4 o-aminotrifluoromethyl ketone 

Relevant articles and documents

QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS

The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is al

ARYL SULFONAMIDES

Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Synthesis and evaluation of analogs of Efavirenz (SUSTIVA(TM)) as HIV-1 reverse transcriptase inhibitors

Efavirenz (SUSTIVA(TM)) is a potent non-nucleoside reverse transcriptase inhibitor. Due to the observation of breakthrough mutations of the reverse transcriptase enzyme during Efavirenz therapy, we sought to develop an optimized second generation series. To that end, SAR of the substituents on the aromatic ring was undertaken and the results are summarized here. The 5,6-difluoro (4f) and the 6-methoxy (4m) substituted benzoxazinones were determined to be equipotent, and as a result such substitution patterns will be incorporated in second generation scaffolds.